Zhejiang Lanyu Digital Technology
301585
BBK Test Systems
301598
Youkeshu Technology
300209
Qingmu Tec Co., Ltd.
301110
Hunan Friendship & Apollo Commercial
002277
CN Stock MarketDetailed Quotes
600518 Kangmei Pharmaceutical
- 2.58
- 0.000.00%
Market to Open Dec 20 09:30 CST
35.77BMarket Cap143.33P/E (TTM)
2.58High2.58Low5.26KlotVolume2.58Open2.58Pre Close1.36MTurnover0.00%Turnover Ratio368.57P/E (Static)13.86BShares2.9552wk High5.08P/B35.12BFloat Cap1.6852wk Low2.84Limit Up13.61BShs Float26.28Historical High2.32Limit Down0.00%Amplitude0.00Historical Low--Dividend TTM2.58Avg Price0lotAsk--Div YieldTTM100Lot Size0lotBid
Kangmei Pharmaceutical Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 9.60%3.87B | 4.09%2.47B | 5.01%1.2B | 16.60%4.87B | 29.84%3.53B | 33.62%2.38B | 22.50%1.14B | 0.67%4.18B | -11.80%2.72B | -14.04%1.78B |
| Operating revenue | 9.60%3.87B | 4.09%2.47B | 5.01%1.2B | 16.60%4.87B | 29.84%3.53B | 33.62%2.38B | 22.50%1.14B | 0.67%4.18B | -11.80%2.72B | -14.04%1.78B |
| Other operating revenue | ---- | -32.01%16.7M | ---- | 149.66%47.3M | ---- | 110.39%24.56M | ---- | -80.82%18.95M | ---- | -81.54%11.67M |
| Total operating cost | 6.31%4.08B | 0.52%2.59B | 3.28%1.27B | 0.10%4.89B | 26.48%3.84B | 30.25%2.58B | 17.79%1.23B | -25.00%4.89B | -30.20%3.03B | -38.44%1.98B |
| Operating cost | 13.27%3.33B | 7.79%2.11B | 4.58%1.03B | 13.96%4.04B | 29.95%2.94B | 32.15%1.96B | 23.59%982.88M | 1.75%3.55B | -10.13%2.26B | -11.85%1.48B |
| Operating tax surcharges | -36.33%34.37M | -46.55%22.26M | -12.96%11.19M | -240.45%-274.18M | 309.03%53.98M | 56.77%41.64M | -1.91%12.85M | -70.13%195.22M | -72.57%13.2M | -16.95%26.56M |
| Operating expense | -28.44%312.99M | -37.96%191.81M | -7.72%95.76M | 18.24%551.78M | 47.21%437.36M | 66.86%309.16M | 18.46%103.77M | 3.74%466.64M | -13.11%297.11M | -25.56%185.28M |
| Administration expense | -2.27%376M | -3.78%244.84M | 0.38%126.37M | -18.29%502.12M | -17.11%384.72M | -11.35%254.45M | -17.03%125.9M | -28.24%614.49M | -15.40%464.16M | -21.68%287.04M |
| Financial expense | 79.00%-2.87M | 85.71%-1.27M | 81.87%-821.58K | -33.59%27.12M | 32.18%-13.68M | 34.80%-8.92M | 36.08%-4.53M | -96.16%40.84M | -102.29%-20.18M | -101.56%-13.69M |
| -Interest expense (Financial expense) | -8.78%8.55M | -2.67%6.09M | -0.54%2.99M | -28.83%56.15M | 18.79%9.37M | 22.13%6.26M | 17.73%3M | -92.28%78.9M | -99.06%7.89M | -99.39%5.12M |
| -Interest Income (Financial expense) | 50.49%-12.15M | 51.96%-7.84M | 48.69%-4.03M | 23.19%-30.74M | 17.43%-24.54M | 18.62%-16.33M | 20.79%-7.86M | -659.36%-40.03M | -1,301.73%-29.73M | -1,503.53%-20.06M |
| Research and development | -15.00%32.16M | -3.36%22.79M | 9.23%10.36M | 79.27%45.62M | 95.81%37.84M | 91.72%23.58M | 141.65%9.49M | 174.41%25.45M | 70.48%19.33M | 44.01%12.3M |
| Credit Impairment Loss | -16.08%55.99M | 560.66%48.91M | 46,711.60%13.58M | 188.87%202.17M | 1,731.73%66.71M | 124.81%7.4M | 99.78%-29.13K | 89.59%-227.48M | 85.40%-4.09M | -0.40%-29.83M |
| Asset Impairment Loss | -159.52%-465.84K | -163.50%-467.4K | -99.54%1.59K | 60.26%-197.55M | 482.85%782.69K | 225.72%736.11K | 91.34%348.36K | 84.43%-497.16M | -117.67%-204.44K | 25.39%-585.5K |
| Other net revenue | 0.46%163.38M | 59.33%138.37M | 121.35%79.11M | 110.04%107.27M | 1,060.31%162.63M | 901.60%86.85M | 1,071.37%35.74M | -108.56%-1.07B | -94.51%14.02M | -104.46%-10.83M |
| Fair value change income | 98.47%-395.39 | 42.44%-10.04K | ---5.26K | ---34.51K | ---25.85K | ---17.45K | ---- | ---- | ---- | ---- |
| Invest income | 91.09%63.65M | 91.10%41.8M | 412.09%29.53M | 5,849.29%44.43M | 24,761.53%33.31M | 285,176.16%21.87M | 95,704.45%5.77M | -99.60%746.87K | -99.92%133.97K | -100.00%7.67K |
| Asset deal income | 37.87%28.21M | 39.23%28.36M | 29.59%26.13M | 1,902.41%19.61M | 3,026.64%20.46M | 3,694.12%20.37M | 6,459.68%20.16M | -98.47%979.19K | -98.59%654.34K | -98.85%536.9K |
| Other revenue | -61.33%16.01M | -45.78%19.78M | 4.10%9.88M | 111.20%38.65M | 136.28%41.4M | 91.62%36.48M | 4.15%9.49M | -101.96%-344.99M | -69.73%17.52M | -60.87%19.04M |
| Operating profit | 70.68%-40.79M | 115.47%18.16M | 118.92%9.59M | 104.88%86.67M | 53.14%-139.12M | 45.07%-117.36M | 55.70%-50.67M | -117.58%-1.78B | 70.42%-296.89M | 76.45%-213.67M |
| Add:Non operating Income | 194.38%66.41M | -47.88%9.1M | -92.15%583.5K | 81.67%57.88M | -21.95%22.56M | -34.56%17.45M | 288.51%7.43M | 30.42%31.86M | 307.34%28.9M | 748.22%26.67M |
| Less:Non operating expense | -59.20%6.52M | -84.35%2.43M | -52.19%508.1K | -96.28%34.18M | -97.37%15.99M | 161.22%15.56M | 65.97%1.06M | -53.62%918.37M | 32,945.70%608.74M | 411.66%5.96M |
| Total profit | 114.41%19.1M | 121.49%24.82M | 121.82%9.66M | 104.14%110.37M | 84.88%-132.55M | 40.16%-115.47M | 60.83%-44.3M | -132.67%-2.66B | 12.19%-876.73M | 78.68%-192.96M |
| Less:Income tax cost | -21.49%10.98M | -30.20%6.7M | -80.75%1.05M | -77.14%6.8M | 68.18%13.99M | 275.97%9.59M | 451.13%5.46M | -87.36%29.75M | -70.88%8.32M | -90.70%2.55M |
| Net profit | 105.53%8.11M | 114.49%18.12M | 117.31%8.61M | 103.84%103.57M | 83.44%-146.54M | 36.03%-125.06M | 55.39%-49.77M | -134.01%-2.69B | 13.83%-885.05M | 79.04%-195.51M |
| Net profit from continuing operation | 105.53%8.11M | 114.49%18.12M | 117.31%8.61M | 103.84%103.57M | 83.44%-146.54M | 36.03%-125.06M | 55.39%-49.77M | -134.01%-2.69B | 13.83%-885.05M | 79.04%-195.51M |
| Less:Minority Profit | 110.52%3.1M | 197.51%2.36M | 77.48%1.14M | 118.54%1.05M | 103.32%1.47M | 488.60%793.21K | 575.89%643.19K | -381.56%-5.64M | 129.44%723.15K | 104.29%134.76K |
| Net profit of parent company owners | 103.39%5.02M | 112.52%15.76M | 114.82%7.47M | 103.81%102.52M | 83.29%-148.01M | 35.67%-125.86M | 54.76%-50.41M | -133.95%-2.69B | 13.55%-885.77M | 78.95%-195.65M |
| Earning per share | ||||||||||
| Basic earning per share | --0 | 111.11%0.001 | 125.00%0.001 | 105.26%0.01 | 82.81%-0.011 | 35.71%-0.009 | 50.00%-0.004 | -133.33%-0.19 | 13.51%-0.064 | 79.10%-0.014 |
| Diluted earning per share | --0 | 111.11%0.001 | 125.00%0.001 | 105.26%0.01 | 82.81%-0.011 | 35.71%-0.009 | 50.00%-0.004 | -133.33%-0.19 | 13.51%-0.064 | 79.10%-0.014 |
| Other composite income | -781.50%-118.14K | -1,878.74%-151.92K | -3,977.41%-21.77K | -158.78%-235.82K | -556.27%-13.4K | 238.16%8.54K | -533.98 | -88.44%401.22K | -98.10%2.94K | -98.41%2.53K |
| Other composite income of parent company owners | -781.50%-118.14K | -1,878.74%-151.92K | -3,977.41%-21.77K | -158.78%-235.82K | -556.27%-13.4K | 238.16%8.54K | ---533.98 | -88.44%401.22K | -98.10%2.94K | -98.41%2.53K |
| Total composite income | 105.45%7.99M | 114.37%17.97M | 117.26%8.59M | 103.84%103.33M | 83.44%-146.55M | 36.04%-125.06M | 55.39%-49.77M | -133.99%-2.69B | 13.81%-885.04M | 79.03%-195.51M |
| Total composite income of parent company owners | 103.31%4.9M | 112.40%15.61M | 114.78%7.45M | 103.81%102.29M | 83.29%-148.02M | 35.67%-125.85M | 54.76%-50.41M | -133.93%-2.69B | 13.54%-885.77M | 78.95%-195.64M |
| Total composite income of minority owners | 110.52%3.1M | 197.51%2.36M | 77.48%1.14M | 118.54%1.05M | 103.32%1.47M | 488.60%793.21K | 575.89%643.19K | -381.56%-5.64M | 129.44%723.15K | 104.29%134.76K |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | Tianji International Accounting Firm (Special General Partnership) | -- | -- | -- | Tianji International Accounting Firm (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
